tirabrutinib
E1549336
UNEXPLORED
Tirabrutinib is a selective small-molecule Bruton’s tyrosine kinase (BTK) inhibitor developed as a targeted therapy for certain B-cell malignancies and autoimmune diseases.
All labels observed (1)
| Label | Occurrences |
|---|---|
| tirabrutinib canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T22690613 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: tirabrutinib Context triple: [BTK, inhibitedBy, tirabrutinib]
-
A.
pirtobrutinib
Pirtobrutinib is a highly selective, non-covalent Bruton tyrosine kinase inhibitor used as a targeted therapy for certain B-cell malignancies.
-
B.
acalabrutinib
Acalabrutinib is a second-generation, highly selective Bruton tyrosine kinase inhibitor used primarily in the treatment of certain B-cell malignancies such as mantle cell lymphoma and chronic lymphocytic leukemia.
-
C.
tucatinib
Tucatinib is an oral small-molecule tyrosine kinase inhibitor used in the treatment of HER2-positive breast cancer, including cases with brain metastases.
-
D.
larotrectinib
Larotrectinib is a targeted cancer therapy that selectively inhibits TRK fusion proteins and is used to treat solid tumors harboring NTRK gene fusions regardless of tumor site.
-
E.
selpercatinib
Selpercatinib is a targeted cancer therapy drug that selectively inhibits RET kinase to treat certain RET-altered thyroid and non-small cell lung cancers.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: tirabrutinib Target entity description: Tirabrutinib is a selective small-molecule Bruton’s tyrosine kinase (BTK) inhibitor developed as a targeted therapy for certain B-cell malignancies and autoimmune diseases.
-
A.
pirtobrutinib
Pirtobrutinib is a highly selective, non-covalent Bruton tyrosine kinase inhibitor used as a targeted therapy for certain B-cell malignancies.
-
B.
acalabrutinib
Acalabrutinib is a second-generation, highly selective Bruton tyrosine kinase inhibitor used primarily in the treatment of certain B-cell malignancies such as mantle cell lymphoma and chronic lymphocytic leukemia.
-
C.
tucatinib
Tucatinib is an oral small-molecule tyrosine kinase inhibitor used in the treatment of HER2-positive breast cancer, including cases with brain metastases.
-
D.
larotrectinib
Larotrectinib is a targeted cancer therapy that selectively inhibits TRK fusion proteins and is used to treat solid tumors harboring NTRK gene fusions regardless of tumor site.
-
E.
selpercatinib
Selpercatinib is a targeted cancer therapy drug that selectively inhibits RET kinase to treat certain RET-altered thyroid and non-small cell lung cancers.
- F. None of above. chosen
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.